<DOC>
	<DOCNO>NCT01132664</DOCNO>
	<brief_summary>This study ass safety efficacy BKM120 combination trastuzumab patient relapse HER2 overexpressing breast cancer previously fail trastuzumab . The study assess safety preliminary efficacy BKM120 combination trastuzumab capecitabine patient relapse HER2 overexpressing breast cancer brain metastasis ( BM ) previously fail trastuzumab .</brief_summary>
	<brief_title>Phase 1b/2 Study BKM120 Plus Trastuzumab Patients With HER2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>World Health Organization ( WHO ) Performance Status ≤ 2 Patients HER2+ breast cancer local laboratory testing ( immunohistochemistry [ IHC ] 3+ stain fluorescence situ hybridization [ FISH ] confirmation IHC 2+ 1+ ) Documented tumor resistance trastuzumab : Recurrence trastuzumab within 12 month since last infusion patient receive trastuzumab adjuvant treatment Progression within 4 week since last infusion trastuzumab patient receive trastuzumab metastatic disease . Documented evidence progressive disease per Response Evaluation Criteria Solid Tumors ( RECIST ) trastuzumabbased therapy define : Phase Ib : time study entry Phase II : within 16 week date first dose Received least 1 4 prior anitHER2 base regimen include least 1 regimen contain trastuzumab ( adjuvant neoadjuvant trastuzumab consider one prior regimen ) . HER2 direct therapy define comprise trastuzumab , lapatinib , trastuzumabDM1 ( TDM1 ) . • Phase II : trastuzumab , TDM1 lapatinib must part recent line therapy Previous line cytotoxic chemotherapy : Phase Ib : 4 line cytotoxic chemotherapy Phase II : 3 line cytotoxic chemotherapy Measurable disease : Phase Ib : patient least one measurable lesion nonmeasurable disease define per RECIST Phase II : patient least one measureable lesion define per RECIST || Specific Inclusion Criteria patient BM cohort : Patient evidence progress brain metastasis and/or new metastatic brain lesion ( ) without leptomeningeal disease . Patient receive prior WBRT and/or SRS &gt; 28 &gt; /= 14 day , respectively , prior start study drug patient must recover side effect therapy WHO performance status &lt; /=1 PT INR &lt; /= 1.5 Any number prior HER2directed cytotoxic regimen , recent line may type antineoplastic therapy || Patients untreated brain metastasis Patients acute chronic liver , renal disease pancreatitis Patients peripheral neuropathy ≥ Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 Patients history mood disorder ≥ CTCAE grade 3 anxiety Patient clinical manifest diabetes mellitus steroidinduced diabetes mellitus || Specific Exclusion Criteria patient BM cohorts Prior treatment capecitabine Patient know dihydropyrimidine dehydrogenase ( DPD ) deficiency Patient currently receive treatment EIAED Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HER2</keyword>
	<keyword>BKM120</keyword>
	<keyword>PIK3</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>Herceptin</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>capecitabine</keyword>
	<keyword>open-label</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>Phase I/Phase</keyword>
</DOC>